Join our daily newsletter At The Bell to receive exclusive market insights
- Resonance Health’s (RHT) flagship product, FerriScan, is now available for use on 3T MRI scanning machines
- FerriScan is internationally regarded by clinicians as the “gold standard” to measure liver iron concentration for patients with iron overload disorders
- Up until now, FerriScan has only been available at facilities with 1.5T MRI scanners but as 3T MRI machines are becoming more prevalent, RHT worked to make its product compatible with the new generation machines
- RHT shares end the day 10.3 per cent in the green to close at 7.5 cents
Resonance Health’s (RHT) flagship product, FerriScan, is now available for use on 3T MRI scanning machines.
FerriScan is internationally regarded as the “gold standard” for the measurement of liver iron concentration for patients suffering iron overload disorders. This accurate MRI-based technique is non-invasive and removes the need for liver biopsies.
Resonance has completed over 58,000 FerriScan analyses to help patients suffering iron overload disorders around the world.
Until now, the FerriScan service has only been available at MRI facilities with 1.5 tesla (1.5T) field strength MRI machines.
With 3T MRI machines being more advanced and becoming more prevalent in hospitals and MRI centres globally, the company began studies to adapt the FerriScan technology from 1.5T to 3T MRI scanners.
In Europe and North America for example, 3T MRI scanners represent 15 to 18 per cent of total MRI scanners. Therefore, Resonance concluded that making FerriScan available for use on 3T MRI machines is a strategic way to grow diagnostic clinical trial contracts and revenue.
Resonance is also progressing the adaptation of its artificial intelligence product, FerriSmart, to 3T MRI scanning machines. This will further enhance availability and convenience for clinicians and patients in large new markets.
RHT shares ended the day 10.3 per cent in the green to close at 7.5 cents.
